Kerkau, Thomas

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis

Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine

T-cell and B-cell ImmunologyMultiple Sclerosis Research Studies

Cited by 203

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.

Lühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., et al. (2003) · The Journal of Experimental Medicine

T-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies Research

Cited by 193

Myocardial aging as a T-cell–mediated phenomenon

Ramos, G. C., van den Berg, A., Nunes-Silva, V., Weirather, J., Peters, L., Burkard, M., Friedrich, M., Pinnecker, J., Abeßer, M., Heinze, K. G., et al. (2017) · Proceedings of the National Academy of Sciences

Cardiac Fibrosis and RemodelingAtherosclerosis and Cardiovascular Diseases

Cited by 168